Abstract 1090P
Background
The interferon gamma gene signature (IFNg) has been shown to be predictive and prognostic in patients (pts) with macroscopic stage III or IV melanoma. In macroscopic stage III melanoma, IFNg from lymph node biopsies (LN-IFNg) might be used in the future for neoadjuvant treatment decisions (combination vs monotherapy). To address the question of whether the IFNg can be analyzed using primary tumor material (P-IFNg) instead of LN-IFNg or, in the case of incongruencies, has a higher predictive value when combined with LN-IFNg, we analyzed the IFNg signature in paired samples (P and LN) from stage III melanoma pts.
Methods
Paraffin primary tumor tissue from pts with stage III melanoma, treated in the OpACIN-neo, PRADO and DONIMI trials (neoadjuvant anti-PD1 +/- anti-CTLA4 +/- domatinostat), was retrospectively analyzed with the nanostring nCounter PanCancer immune profiling panel and compared to fresh frozen LN biopsies. The cut-off was calculated based on event-free survival (EFS) using maximally selected rank statistics.
Results
Forty-four pts were included: the majority had a superficial spreading melanoma (68%), with a median Breslow thickness of 1.9mm (IQR: 1.1–2.9), ulceration of 23% and 57% had a BRAF mutation. The median time from primary tumor to trial registration was 21.8 months (IQR: 8.1-48.0). P-IFNg had a low correlation with LN-IFNg (r=0.33, p=0.03). High P-IFNg showed significantly prolonged DMFS and the same trend for EFS, RFS and OS (Table). Pts with concurrent high P- and LN-IFNg had 3 year-EFS of 95% as compared to 88% for pts with LN-IFNg high only, suggesting that addition of P-IFNg could improve selection of pts with better outcomes. Table: 1090P
| Low P-IFNg (n=14) | High P-IFNg (n=28) | Log rank p-value | Low LN-IFNg (n=15) | High LN-IFNg (n=27) | Log rank p-value | Low LN-IFNg &/or low P-IFNg (n=22) | High LN-IFNg & P-IFNg (n=20) | Log rank p-value | |
| 36 month(m) EFS | 48% | 79% | 0.084 | 33% | 88% | ConclusionsOur results suggest that pts with concurrently high IFNg-signature expressions (high IFNg in P and LN) have a better outcome than LN-IFNg high pts only. If confirmed, these findings could inform treatment selection and prognosis. Clinical trial identificationNCT02977052; NCT02977052; NCT04133948. Editorial acknowledgementLegal entity responsible for the studyNetherlands Cancer Institute. FundingBMS funded the OpACIN-neo and PRADO trials; 4SC AG funded the DONIMI trial. DisclosureP. DIMITRIADIS: Financial Interests, Personal, Royalties: Signature oncology. I. Reijers: Financial Interests, Personal, Royalties: Signature oncology. B. van de Wiel: Non-Financial Interests, Advisory Role, no activities in last two years: BMS. R.A. Scolyer: Financial Interests, Personal, Advisory Board: SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc, F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc, Bristol Myers Squibb, Myriad Genetics, GSK; Financial Interests, Personal, Full or part-time Employment: Sydney Local Health District; Financial Interests, Personal, Other, Co-Medical Director fee: Melanoma Institute Australia; Financial Interests, Personal, Officer: Bridport Pathology Pty Ltd; Financial Interests, Personal and Institutional, Coordinating PI, Investigator Grant (2022/GNT2018514): National Health and Medical Research Council of Australi. R.P.M. Saw: Financial Interests, Personal, Invited Speaker: Bristol Myers Squib, Novartis; Financial Interests, Personal, Advisory Board: MSD, Novartis, Qbiotics; Financial Interests, Personal, Advisory Board, for MelaSeq-38: Australian Clinical Labs; Financial Interests, Personal, Other, On Faculty, support of University of Sydney salary: Melanoma Institute Australia. A.J. Spillane: Financial Interests, Personal, Invited Speaker, Fee for preparation and delivery of online talk in Oct 2021: Eli Lily Australia. G. Hospers: Financial Interests, Institutional, Advisory Board: BMS, MSD; Financial Interests, Institutional, Research Grant: BMS, Seerave Foundation. A.M. Menzies: Financial Interests, Personal, Advisory Board, advisory board: BMS, MSD, Novartis, Roche, Pierre Fabre, QBiotics. A.C.J. van Akkooi: Financial Interests, Institutional, Advisory Board: Amgen, Bristol Myers Squibb, Novartis, MSD, Merck, Merck - Pfizer, Pierre Fabre, Sanofi, Sirius Medical, 4SC, Provectus; Financial Interests, Personal, Advisory Board: Neracare, SkylineDx; Financial Interests, Institutional, Research Grant, NIVEC study: Amgen; Financial Interests, Institutional, Research Grant: Merck - Pfizer. W. Van Houdt: Financial Interests, Institutional, Invited Speaker: Amgen, Boehringer Ingelheim Ingelheim; Financial Interests, Institutional, Advisory Board: Belpharma, Sanofi, MSD; Financial Interests, Personal, Other, travel grant: Novartis; Financial Interests, Institutional, Local PI: BMS; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Funding: Sirius. G.V. Long: Financial Interests, Personal, Other, Consultant Advisor: Agenus Inc, Amgen Inc, Array Biopharma Inc, AstraZeneca UK Limited, Bayer Healthcare Pharmaceuticals, BioNTech SE, Boehringer Ingelheim Ingelheim International GmbH, Bristol Myers Squibb, Evaxion Biotech A/S, Hexal AG, Highlight Therapeutics S.L, IOBiotech, Immunocore Ireland Limited, Innovent Bioilogics USA Inc, Merck Sharp & Dohme, Novartis Pharma AG, PHMR Limited, Pierre Fabre, Regeneron Pharmaceuticals Inc, Scancell Limited, SkylineDX B.V; Non-Financial Interests, Principal Investigator, GL is PI on over 30 clinical trials: GL is PI on over 30 clinical trials. C.U. Blank: Financial Interests, Institutional, Advisory Board: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre; Financial Interests, Personal, Advisory Board: Third Rock Ventures; Financial Interests, Personal, Stocks/Shares: Immagene; Financial Interests, Personal, Stocks/Shares, intention to develop IFN signature algorithm: Signature Oncology; Financial Interests, Institutional, Coordinating PI: NanoString, BMS, Novartis, 4SC; Other, Other, pending patent: WO 2021/177822 A1. All other authors have declared no conflicts of interest. Resources from the same session1132P - Regorafenib in Caucasian patients with pretreated advanced KIT-mutant melanoma: A dual center case seriesPresenter: Iris Dirven Session: Poster session 04 1133P - Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registryPresenter: Juergen Becker Session: Poster session 04 1134P - Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200Presenter: Celeste Lebbe Session: Poster session 04 1135P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment of Merkel cell carcinomaPresenter: Maximilian Haist Session: Poster session 04 1136P - Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal studyPresenter: Eva Muñoz-Couselo Session: Poster session 04 1137P - Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitorsPresenter: Justine Cohen Session: Poster session 04 1138P - A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parametersPresenter: Rikke Holmstroem Session: Poster session 04 1139TiP - IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanomaPresenter: Marcus Butler Session: Poster session 04 1140TiP - Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumabPresenter: Joséphine Janssen Session: Poster session 04 1210P - Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 studyPresenter: Marina Garassino Session: Poster session 04 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|